Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina K. Singh, Terri L. Parker, Alexander Menter, Xuezhong Yang, Benjamin M. Parsons, Pankaj Kumar, Prashant Kapoor, Aaron S. Rosenberg, Jeffrey A. Zonder, Edward A. Faber, Sagar Lonial, Kenneth C. Anderson, Paul G. Richardson, Robert Z. Orlowski, Lynne I. Wagner, S. Vincent Rajkumar